PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024
PR NewswireMay 23, 2024
Presentation at ARVO 2024 gained attention as Eylea (aflibercept) eye drops demonstrated similar efficacy to intravitreal injections in animal studies. DAEJEON, South Korea, May 23, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced that its U.S. subsidiary, Wincal Biopharm, Inc. ("WincalBio"),